Filing Details

Accession Number:
0001104659-12-007036
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-02-06 20:25:05
Reporting Period:
2011-12-22
Filing Date:
2012-02-06
Accepted Time:
2012-02-06 20:25:05
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1382911 Orexigen Therapeutics Inc. OREX Pharmaceutical Preparations (2834) 651178822
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1280249 Iii K Daniel Turner C/o Orexigen Therapeutics, Inc.
3344 N. Torrey Pines Court, Suite 200
La Jolla CA 92037
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-12-22 28,602 $1.45 177,958 No 4 P Indirect See Footnote
Common Stock Acquisiton 2011-12-22 28,602 $1.45 377,958 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Warrant to Purchase Common Stock Acquisiton 2011-12-22 28,602 $14.49 286,020 $0.00
Common Stock Warrant to Purchase Common Stock Acquisiton 2011-12-22 28,602 $14.49 286,020 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
28,602 2011-12-22 2021-12-22 No 4 P Indirect
28,602 2011-12-22 2021-12-22 No 4 P Indirect
Footnotes
  1. The Common Stock and Warrants were sold as units at a purchase price of $15.94 per unit, each unit consisting of one share of Common Stock and one Warrant to purchase ten shares of Common Stock.
  2. The reported securities are owned directly by Montreux Equity Partners II SBIC, L.P. ("MEP II"). The voting and disposition of the shares held by MEP II are determined by Montreux Equity Management II SBIC, LLC ("MEM II"). Mr. Turner is a managing member of MEM II. Mr. Turner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
  3. The reported securities are owned directly by Montreux Equity Partners III SBIC, L.P. ("MEP III"). The voting and disposition of the shares held by MEP III are determined by Montreux Equity Management III SBIC, LLC ("MEM III"). Mr. Turner is a managing member of MEM III. Mr. Turner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.